Milestones

• SYMLIN™ – Report titration study data

• SYMLIN™ – NDA amendment

• GLP-1 – Phase 2 data

• AC2993 – Initial Phase 3 results

• AC2993 LAR – Start additional Phase 2 studies

• AC2993 – Complete Phase 3

• AC162352 (PYY [3-36]) – Submit IND

• SYMLIN™ – FDA decision expected

• SYMLIN™ – Launch, subject to FDA approval

• AC2993 – NDA

2003

2004

1Q

2Q

4Q

3Q

2H

1H

Previous slide

Next slide

Back to first slide

View graphic version